"10.1371_journal.pone.0123969","plos one","2015-04-17T00:00:00Z","Michelle C Crank; Ingelise J Gordon; Galina V Yamshchikov; Sandra Sitar; Zonghui Hu; Mary E Enama; LaSonji A Holman; Robert T Bailer; Melissa B Pearce; Richard A Koup; John R Mascola; Gary J Nabel; Terrence M Tumpey; Richard M Schwartz; Barney S Graham; Julie E Ledgerwood; the VRC 308 Study Team","Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America; Influenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America","Conceived and designed the experiments: JL BG ME GN JM RK RS TT MP. Performed the experiments: IG LH MP RS BG JL RB ME TT RK RB. Analyzed the data: MC ZH JL GY SS ME RB TT MP RL. Contributed reagents/materials/analysis tools: RS RK RB TT. Wrote the paper: MC JL GY SS BG JM ME TT MP LH RK.","The authors would like to clarify the affiliation and address competing interests and financial disclosure of one of the authors, Dr. Gary Nabel. Dr. Gary Nabel is currently employed by Sanofi, USA, however his involvement in the planning of the clinical trial and any significant input on the manuscript were completed while he was employed at the Vaccine Research Center, NIAID, NIH. Dr. Nabel is named on patent applications for the CMV-R promotor used in the vaccine in the manuscript. The identification number for the patent is as follows: US 7,094,598. There are no further patents, products in development or marketed products to declare. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials.","2015","04","Michelle C Crank","MCC",17,TRUE,9,10,10,11,TRUE,TRUE,FALSE,0,NA,FALSE
